Pharmaceutical and Safety Profile Evaluation of Novel Selenocompounds with Noteworthy Anticancer Activity

Prior studies have reported the potent and selective cytotoxic, pro-apoptotic, and chemopreventive activities of a cyclic selenoanhydride and of a series of selenoesters. Some of these selenium derivatives demonstrated multidrug resistance (MDR)-reversing activity in different resistant cancer cell...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2022-02, Vol.14 (2), p.367
Main Authors: Marć, Małgorzata Anna, Domínguez-Álvarez, Enrique, Latacz, Gniewomir, Doroz-Płonka, Agata, Sanmartín, Carmen, Spengler, Gabriella, Handzlik, Jadwiga
Format: Article
Language:English
Subjects:
ADMET
anticancer activity
Antioxidants
Cancer therapies
Cell cycle
Disease prevention
Drug dosages
Free radicals
Hydrocarbons
metabolic stability
Metabolism
Mutation
PAMPA
Permeability
pharmaceutical profile
Pharmaceuticals
Prostate
R&D
Research & development
Salmonella
Selenium
selenoesters
Thyroid gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prior studies have reported the potent and selective cytotoxic, pro-apoptotic, and chemopreventive activities of a cyclic selenoanhydride and of a series of selenoesters. Some of these selenium derivatives demonstrated multidrug resistance (MDR)-reversing activity in different resistant cancer cell lines. Thus, the aim of this study was to evaluate the pharmaceutical and safety profiles of these selected selenocompounds using alternative methods in silico and in vitro. One of the main tasks of this work was to determine both the physicochemical properties and metabolic stability of these selenoesters. The obtained results proved that these tested selenocompounds could become potential candidates for novel and safe anticancer drugs with good ADMET parameters. The most favorable selenocompounds turned out to be the phthalic selenoanhydride ( ), two ketone-containing selenoesters with a 4-chlorophenyl moiety ( and ), and a symmetrical selenodiester with a pyridine ring and two selenium atoms ( ).
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14020367